Filing Flows

Filing Flows › 8-K events › Envoy Medical

Envoy Medical: regulation fd disclosure

Form 8-K filed Oct 27, 2026 · items 3.03, 5.03, 7.01

FDA decisionsEnvoy Medical Announces Reverse Stock Split

What the filing says

White Bear Lake, Minnesota – October 22, 2026 – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A co

Read the filing on SEC EDGAR →

What usually followsAcross 1,456 8-Ks reporting Item 3.03 (change to shareholders’ rights) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.2%. Item 5.03: +0.1% next session across 5,869. Every item ranked →

Envoy Medical at a glance

Latest quarterQ3 2026
Revenue$66K
Revenue Y/Y+57%
Operating marginn/m
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies

Envoy Medical, Q3 2026: revenue $66K (+57% year over year). The chart follows the revenue to costs, profit and cash.

Envoy Medical: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.